Convexia
YC S25San Francisco, US · Founded 2025 · 4 employees · Hiring · 1 known investors
Convexia provides AI-powered drug discovery and evaluation software that scans global sources for overlooked drug assets and runs deep in silico simulations across 50+ models to assess binding, toxicity, pharmacokinetics, and immunogenicity. The platform combines AI agents with expert human review to accelerate drug asset evaluation for biotech companies, pharma firms, and venture investors.
AI & Machine LearningBiotechDeep TechHealthtechAI-powered Drug DiscoveryDrug DeliveryUnited States of AmericaAmerica / Canada
Founders & leadership· Y Combinator alumni (S25)
Convexia was founded in 2025 by Ayaan Parikh and Rahul Vijayan.
AP
Ayaan ParikhinCo-Founder & CEOAyaan Parikh holds degrees in computer science and biology from Stanford. He has founded three healthtech startups spanning telemedicine, addiction recovery, and hydroponic systems, and has published research on molecular dynamics. His background also includes experience in biotech venture capital and consulting.
RV
Rahul VijayaninCo-Founder & CTORahul Vijayan studied computer science and economics at Stanford. He previously founded three healthtech companies in telemedicine, recovery optimization, and agricultural systems.
Investors · 1
The YC application· Summer 2025 batch
Alumni Q&A
- How did your company get started? (i.e., How did the founders meet? How did you come up with the idea? How did you decide to be a founder?)
- The two founders, Ayaan and Rahul, met at an entrepreneurship conference in 8th grade and have built companies together since. They launched two startups during high school and a third at Stanford, which was later acquired. Convexia is their fourth venture.
Summarized from the founders' answers on their Y Combinator profile.
Competitors · 2
by search overlapEvecxia3 shared keywordsEvecxia Therapeutics develops 5-HTP-based drugs using proprietary drug delivery technologies designed to increase brain serotonin production as adjunctive treatments for depression and other mental disorders. Its therapies target patients with disabling mental illness not adequately treated by existing antidepressants such as SSRIs and SNRIs.
Cybrexa, Inc.3 shared keywordsCybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.
Companies competing with Convexia for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Convexia do?
- Convexia provides AI-powered drug discovery and evaluation software that scans global sources for overlooked drug assets and runs deep in silico simulations across 50+ models to assess binding, toxicity, pharmacokinetics, and immunogenicity. The platform combines AI agents with expert human review to accelerate drug asset evaluation for biotech companies, pharma firms, and venture investors.
- Who founded Convexia?
- Convexia was founded by Ayaan Parikh, Rahul Vijayan in 2025.
- Who are Convexia's investors?
- Convexia's investors include Y Combinator.
- Where is Convexia headquartered?
- Convexia is headquartered in San Francisco, US.